The company resumes cash dividend payment from 2013

Grifols holds its Ordinary General Shareholders’ Meeting

- Shareholders endorse the actions of the management team and ratify all the items on the agenda
- The Board of Directors agrees to distribute an interim dividend for the financial year 2013 of 0.20 Euros for each Class A and Class B share
- The number of board members is increased to 12 with the appointment of Belén Villalonga Morenés as new external independent member of the board and of the Audit Committee

Barcelona, May 24, 2013: Grifols (MCE:GRF,MCE:GRF.P and NASDAQ:GRFS), one of the world’s leading companies in the production of plasma-derived biological medicines has held its Ordinary General Shareholders’ Meeting on second call. 628 shareholders, representing 126,405,748 Class A shares and 59.3% of the Company’s share capital with voting rights, were represented at the meeting.

The votes delegated to the Board of Directors represented more than 46% of the share capital, confirming the support of shareholders to the group’s management and its business plan, the main focus of which during 2012 was to encourage international growth, secure the production capacities and the technical and human resources necessary to ensure organic growth, and promote new strategic R & D lines, among which is a global and comprehensive approach to Alzheimer's disease.

Key items on the meeting’s agenda included:

- The approval of the annual accounts, both individual and consolidated, consisting of balance sheet, profit and loss account, statement of changes in net equity, cash flow, and the corresponding Directors’ reports.
- The distribution of the mandatory dividend for non-voting shares (Class B), which amounts to 0.01 Euros per share and which will be paid as of May 29, 2013.
- The reappointment of auditors.
- The appointment of Belén Villalonga Morenés as new external independent member of Grifols’ board for the statutory period of five years, which involves increasing the number of Members of Board of Directors of the company to twelve. The new board member will also form part of the Audit Committee.

Finally, shareholders ratified remuneration for non-executive directors who do not provide any professional paid services to the company during the year that amounts to 100,000 Euros gross for 2013.

The Board of Directors of Grifols has reported and explained to shareholders the latest capital increase carried out, which forms part of the agreement to purchase 60% of Progenika Biopharma, that increased the nominal amount by 88,499.7 Euros through the
issuance and circulation of 884,997 new non-voting shares (Class B) with a nominal value of 0.10 Euros each.

After the increase, Grifols’ share capital amounts to 119.6 million Euros and is represented by 213,064,899 ordinary shares (Class A) with a nominal value of 0.50 Euros per share, and 130,712,555 non-voting shares (Class B) with a nominal value of 0.10 Euros per share.

Grifols’ ordinary shares (Class A) are listed on the Spanish Stock Exchange, and they are a component of the main index, Ibex-35 (GRF), while Grifols’ non-voting shares (Class B) are listed on the Spanish Stock Exchange (GRF.P) and on the NASDAQ (GRFS) via ADRs (American Depositary Receipts). The ratio of exchange is one Grifols ADR to one Class B share.

**Grifols maintains its commitment to shareholders and resumes cash dividend payment from 2013**

Grifols Board of Directors has agreed to pay an ordinary interim dividend for the financial year 2013 of 0.20 Euros gross for each Class A and Class B share, allocating a total initial amount of 68.75 million Euros to dividends. In this way the company resumes its policy of paying out dividends to shareholders.

This amount will be paid in a single payment as of June 5, 2013 through Iberclear and its participating entities, with BBVA acting as the paying entity.

Grifols fulfills its commitment to maintaining the highest compensation for shareholders who, as a sign of confidence in the management and future of the company, approved the allocation to voluntary reserves of the total amount of the profits achieved in the last two years, obtaining bonus shares (Class B) in return.

Debt reduction remains a priority for Grifols and the company sustains the strategy to rapidly reduce the leverage ratio. The modifications to the financial structure negotiated by the group in the first quarter of 2012, included several improvements to the terms and conditions of the credit agreement to finance the acquisition of Talecris and changed the leverage ratio (Net Financial Debt / EBITDA) which limited the distribution of cash dividends.

**About Grifols**

Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.

As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.

In 2012, Grifols’ sales exceeded 2,620 million euros. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting
class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit [www.grifols.com](http://www.grifols.com)

**DISCLAIMER**

The facts and figures contained in this report which do not refer to historical data are "projections and forward-looking statements". The words and expressions like "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "try to achieve", "estimate", "future" and similar expressions, insofar as they are related to Grifols Group, are used to identify projections and forward-looking statements. These expressions reflect the assumptions, hypothesis, expectations and anticipations of the management team at the date of preparation of this report, which are subject to a number of factors that could make the real results differ considerably. The future results of Grifols Group could be affected by events related to its own activity, such as shortages of raw materials for the manufacture of its products, the launch of competitive products or changes in the regulations of markets in which it operates, among others. At the date of preparation of this report Grifols Group has adopted the measures it considers necessary to offset the possible effects of these events. Grifols, S.A. does not assume any obligation to publicly inform, review or update any projections and forward-looking statements to adapt them to facts or circumstances following the preparation of this report, except as specifically required by law.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities Market Law 24/1988, of July 28, the Royal Decree-Law 5/2005, of March 11, and/or Royal Decree 1310/2005, of November 4, and its implementing regulations.